Indivior Pharmaceuticals, Inc. (INDV) /
The cash flow of Indivior Pharmaceuticals, Inc. over the past 4 years
Chart Indivior Pharmaceuticals, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2022–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Indivior Pharmaceuticals, Inc.'s operating cash flow was -$27M and its capital expenditures $66M, leaving free cash flow of -$93M. Free cash flow was above zero in 1 of the 4 years shown. It ranged from -$308M in fiscal 2023 to $7M in fiscal 2024. Capital expenditures were highest in fiscal 2025, at $66M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$27M | $66M | -$93M |
| 2024ended Dec 31, 2024 | $36M | $29M | $7M |
| 2023ended Dec 31, 2023 | -$300M | $8M | -$308M |
| 2022ended Dec 31, 2022 | -$4M | $5M | -$9M |
Fiscal years as Indivior Pharmaceuticals, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Indivior Pharmaceuticals, Inc.
- The revenue of Indivior Pharmaceuticals, Inc.
- The profitability of Indivior Pharmaceuticals, Inc.
- All of Indivior Pharmaceuticals, Inc.'s financials, charted
Companies of a similar size
- LOPEGRAND CANYON EDUCATION, INC.
- CORZCore Scientific, Inc./tx
- CRVLCORVEL CORPORATION
- APLEAPPLE HOSPITALITY REIT, INC.
- KGSKodiak Gas Services, Inc.
Not investment advice. This page shows what Indivior Pharmaceuticals, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.